14 June Duke-Margolis workshop + A taxonomy for non-traditional (non-Fleming) antimicrobials

Dear All: (18 June addendum: the materials from the meeting are now posted!)

First, planning continues apace for the 14 June Duke-Margolis workshop on non-traditional products. There is now a link for registration, confirmation that the event is going to be webcast, and a draft agenda. Mark your calendar now to attend either in person or via the webcast!

Second, I would like to expand a bit on my very brief 23 Apr 2018 post on the discussion of non-traditional products at the CARB-X– and GARDP-sponsored ECCMID symposium on regulatory issues. The full talk can be found here and was based on conversations with multiple colleagues (see list on slide 4). The key ideas are:

1. “Non-traditional” covers a lot of territory and it is helpful to refine the idea by envisioning a continuum for antimicrobial therapeutic products that runs from Fleming to non-Fleming products:

  • Fleming: A product that is like a penicillin in that it has the spectrum for a defined syndrome and the speed required to be suitable as standalone therapy (SSSS, if you like acronyms). Importantly, this means that standard non-inferiority trial designs can be used as the basis for registration.
  • Non-Fleming = Everything else = Non-traditional. This can include phage, antibodies, small molecules, large molecules, microbiome … it’s non-Fleming because it lacks one or more of the spectrum-syndrome-speed-standalone properties of a Fleming .

2. Digging more deeply, it then becomes helpful to replace the ambiguous terms alternative to antibioticspotentiator, and enhancer with four functional archetypes for the non-Fleming therapeutic products: Create, Transform, Enhance, and Restore:

Picture

To emphasize, this taxonomy of non-Fleming antimicrobial products is entirely functional:  physical nature of the product (large, small, phage, etc.) is not relevant! Rather, the behavior of the product defines the opportunities it brings and the challenges it faces. You should review the entire talk, but here’s a quick summary:

  • The archetypes Create and Enhance have the advantage of often being really novel, but the challenges of often being narrow, not standalone, requiring superiority study designs, and not being able to use an MIC as the basis for PK-PD thinking.
  • Conversely, the archetypes Transform and Restore have the advantages of leveraging a known component, of being able to leverage an MIC for PK-PD, and often being suitable for standalone development despite the challenge of sometimes being very narrow in terms of spectrum.

3. Agents for prevention are a distinct category and the Fleming/Non-Fleming idea is really not relevant. Instead, the problem is the general challenge of showing an advantage over best Standard of Care. See the slide deck for a specific example. 

OK, that’s enough for now … I look forward to the conversation on 14 June where we will hopefully expand further on the challenges around non-traditional products!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

Leaky pipe(line)s, Part 2 / CARB-X reboot / WHO 2021 pipeline review

Dear All, We have a 3-part discussion today on the theme of “I want a new drug … so how do I find it?” Off we go! First, the 14 June 2022 newsletter entitled “Leaky Pipe(lines) / When Is A Molecule A Drug” generated further discussions that are worth sharing: It was noted the microdosing

Antibiotic procurement models for LMICs / G7 Leaders call for Pull!

Dear All, Two stops on our tour today: (i) an excellent survey of incentive models and (ii) a final communique from the recent G7 meetings. First up, CGD (Center for Global Development) have released a report (link) entitled “Leveraging Purchasing Systems to Ensure Access, Stewardship, and Innovation: A Landscape Review of Current and Potential Market Structures

Leaky pipe(lines) / When is a molecule a drug? (Part 1 of 2)

Dear All, I was fascinated by this recent paper in AAC: Neha K. Prasad, Ian B. Seiple, Ryan T. Cirz, and Oren S. Rosenberg. Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020. Antimicrob Agents Chemother. 2022 May 17;66(5):e0005422. doi:10.1128/aac.00054-22. (Addendum: This newsletter has a follow-up newsletter.) In brief,

FDA/CVM: Antimicrobial use in companion animals

Dear All, Post-newsletter addendum: I’ve learned that USDA will host a 10 Aug 2022 (virtual, 10a-4.30p ET) workshop on AMR in food agriculture. See the meetings calendar for more details; go here to register. I’ll confess to having missed entirely the request back in February 2022 from FDA’s Center for Veterinary Medicine (CVM) for comments on antimicrobial

Scroll to Top